There is a lot of variation in how patients with acute myeloid leukemia (AML) react to the disease, and to its treatment. There are three main approaches to managing AML, and assessing the risks and benefits of each approach is crucial for making treatment decisions. Risk stratification involves assessing a patient’s age, health, and overall underlying conditions.
Jennifer Marvin-Peek, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses practical considerations for treating patients with IDH-mutated acute myeloid leukemia. Dr Marvin-Peek highlights the…
Naval G. Daver, MD, an associate professor in the Department of Leukemia, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses maintenance chemotherapy…
Eunice Wang, MD, Chief of the Leukemia Service at Roswell Park Comprehensive Cancer Center, describes acute myeloid leukemia (AML) and details how emerging targeted treatments are transforming the…
Tara Lin, MD, University of Kansas Medical Center, Kansas City, Kansas, discusses how she approaches choosing induction therapy for patients with treatment-related acute myeloid leukemia, emphasizing that fitness…
Can targeted therapies offer safer and more efficient means to treat patients with acute myeloid leukemia (AML)? Eunice Wang, MD, Chief of the Leukemia Service at Roswell Park…
